Published in Leuk Lymphoma on March 01, 2007
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood (2014) 1.42
What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma? Leuk Lymphoma (2007) 0.75
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? Eur J Haematol (2003) 1.41
Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. J Psychosom Res (2006) 1.21
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica (2008) 1.07
Primary breast lymphoma: an uncommon but curable disease. Leuk Lymphoma (2003) 0.96
Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma (2004) 0.89
The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol (2012) 0.89
SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett (2009) 0.87
TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer (2009) 0.87
MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother (2012) 0.86
Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol (2009) 0.85
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One (2011) 0.83
Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol (2012) 0.83
Bilateral central retinal vein occlusion associated with multiple myeloma. Ophthalmologica (2004) 0.81
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immun (2011) 0.80
Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol (2004) 0.80
Comparative expression of a set of genes to an internal housekeeping control in CDNA amplified and not amplified by PolyAPCR in non-Hodgkin's lymphoma samples obtained from fine-needle aspiration cytology. Diagn Mol Pathol (2010) 0.79
Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leuk Lymphoma (2005) 0.79
Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. Cancer Immunol Immunother (2012) 0.78
p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett (2004) 0.78
Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients. Leuk Lymphoma (2004) 0.78
Advances in the treatment of multiple myeloma: the role of thalidomide. Leuk Lymphoma (2003) 0.77
Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. Leuk Lymphoma (2009) 0.77
Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncol (2002) 0.77
Histological classification of 1,025 cases of Hodgkin's lymphoma from the State of São Paulo, Brazil. Sao Paulo Med J (2005) 0.76
Essential thrombocythemia after treatment of non-Hodgkin's lymphoma. Leuk Res (2007) 0.76
Understanding myeloma cancer stem cells. Immunotherapy (2013) 0.76
Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. Histol Histopathol (2009) 0.76
2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol (2003) 0.76
Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics (Sao Paulo) (2011) 0.76
Mutations in NPC1 in two Brazilian patients with Niemann-Pick disease type C and progressive supranuclear palsy-like presentation. Mov Disord (2006) 0.75
Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. Leuk Lymphoma (2010) 0.75
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol (2003) 0.75
Correlation between histological subtype and type of bcl-2/IgH rearrangement in follicular lymphomas. Leuk Lymphoma (2004) 0.75
Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica (2004) 0.75
Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. Leuk Lymphoma (2013) 0.75
Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant. Leuk Lymphoma (2013) 0.75